The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line.
about
Amygdalin blocks bladder cancer cell growth in vitro by diminishing cyclin A and cdk2Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancerExploiting p70 S6 kinase as a target for ovarian cancer.Potential therapeutic effects of mTOR inhibition in atherosclerosis.Intensified antineoplastic effect by combining an HDAC-inhibitor, an mTOR-inhibitor and low dosed interferon alpha in prostate cancer cells.Molecular analysis of sunitinib resistant renal cell carcinoma cells after sequential treatment with RAD001 (everolimus) or sorafenib.HDAC-inhibition counteracts everolimus resistance in renal cell carcinoma in vitro by diminishing cdk2 and cyclin A.Resistance to the mTOR inhibitor temsirolimus alters adhesion and migration behavior of renal cell carcinoma cells through an integrin α5- and integrin β3-dependent mechanism.Resistance to the mTOR-inhibitor RAD001 elevates integrin α2- and β1-triggered motility, migration and invasion of prostate cancer cellsContinuous administration of the mTORC1 inhibitor everolimus induces tolerance and decreases autophagy in mice.Cross-communication between histone H3 and H4 acetylation and Akt-mTOR signalling in prostate cancer cells.A naturally derived small molecule disrupts ligand-dependent and ligand-independent androgen receptor signaling in human prostate cancer cells.Diagnostic significance and potential function of miR-338-5p in hepatocellular carcinoma: A bioinformatics study with microarray and RNA sequencing data.p70 Ribosomal protein S6 kinase (Rps6kb1): an update.Acquired resistance to temsirolimus is associated with integrin α7 driven chemotactic activity of renal cell carcinoma in vitro.HDAC Inhibition Counteracts Metastatic Re-Activation of Prostate Cancer Cells Induced by Chronic mTOR Suppression
P2860
Q28542396-AF5E5ADB-7389-47A4-99B9-45CA0F443E66Q37580261-DF0DF414-ED2F-4342-9636-AEBF8D87D950Q38007998-128977C8-BD20-4C6D-89B6-6B286825D53EQ38628797-F94A6629-6BBD-43A9-AC47-061ED684294DQ38895320-C369CDA0-F603-4B1C-905E-A24F20487DA9Q38936109-5BBECE46-FBDF-47D9-9EB9-63F56293986AQ38984146-0284535A-A3EE-440E-B5CE-E3A69BDDDF48Q38991418-3AA40E93-18F8-4FE0-8A50-2B82C514F7E4Q39316852-12779D8C-2840-4959-A3CF-CA031311C167Q39379576-91AA6FA2-C8A2-44A4-9201-EB6F218A5E53Q41874831-74DF984D-7F5C-4E23-80CC-CA6978C5DD4BQ42006737-E80D4EE2-22F0-405D-8DDE-BEAD43EAC851Q47365566-41AFFF83-8857-4524-A3AD-26BD38B65C37Q54332389-825E82ED-49AF-4FB4-BB69-A61F8003DC9BQ55318529-92512CA8-A689-48B9-9619-016B6B6BE2CFQ58773654-D7ADAF61-BDE2-4C77-B294-681FFB35E981
P2860
The cdk1-cyclin B complex is involved in everolimus triggered resistance in the PC3 prostate cancer cell line.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
The cdk1-cyclin B complex is i ...... PC3 prostate cancer cell line.
@en
The cdk1-cyclin B complex is i ...... PC3 prostate cancer cell line.
@nl
type
label
The cdk1-cyclin B complex is i ...... PC3 prostate cancer cell line.
@en
The cdk1-cyclin B complex is i ...... PC3 prostate cancer cell line.
@nl
prefLabel
The cdk1-cyclin B complex is i ...... PC3 prostate cancer cell line.
@en
The cdk1-cyclin B complex is i ...... PC3 prostate cancer cell line.
@nl
P2093
P1433
P1476
The cdk1-cyclin B complex is i ...... PC3 prostate cancer cell line.
@en
P2093
Axel Haferkamp
Christoph Wiesner
Eva Juengel
Georg Bartsch
Igor Tsaur
Jasmina Makarević
Lukasz Hudak
Martin Kurosch
Roman A Blaheta
Sebastian Harder
P356
10.1016/J.CANLET.2011.08.026
P407
P577
2011-09-03T00:00:00Z